Position in DGX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$907,357
+$64,056 QoQ
Shares Held
4,281
-0.5% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#502
of 1,098 holders
Holding Since
Jun 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DGX Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026HARBOR CAPITAL ADVISORS, INC. holds $17,367,922 across 10 Diagnostics & Research names. DGX ranks #4 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RDNT |
RadNet, Inc.
|
116,506 | $7,184,925 | |
| 2 | NEO |
Neogenomics Inc
|
223,846 | $3,265,913 | |
| 3 | VCYT |
Veracyte, Inc.
|
52,337 | $3,073,752 | |
| 4 | DGX |
Quest Diagnostics Inc
This page
|
4,281 | $907,357 | |
| 5 | CSTL |
Castle Biosciences Inc
|
31,748 | $757,189 | |
| 6 | GRAL |
GRAIL, Inc.
|
8,696 | $593,675 | |
| 7 | MYGN |
Myriad Genetics Inc
|
97,375 | $556,011 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
2,831 | $547,005 |
All Filings in DGX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $907,357 | 4,281 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $843,301 | 4,303 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $544,884 | 3,140 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $596,134 | 3,128 | Shares | Sole | 2025-10-15 | |
| 2025-06-30 | $1,938,028 | 10,789 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $1,813,824 | 10,720 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $1,528,815 | 10,134 | Shares | Sole | 2025-01-10 | |
| 2024-09-30 | $1,578,737 | 10,169 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $647,853 | 4,733 | Shares | Sole | 2024-07-09 | |
| 2024-03-31 | $160,530 | 1,206 | Shares | Sole | 2024-05-13 | |
| 2023-06-30 | $19,537 | 139 | Shares | Sole | 2023-07-11 | |
| No filing history on record for this holder in this stock. | ||||||